16 completed, 5 terminated, 1 not yet recruiting, 1 recruiting. 24 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Completed 16, Terminated 5, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Fungemia: new trials by email Literature Review of Fungemia trials Research Report on Fungemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of a Short Duration Therapy for Candidemia Standard of Care (SOC), Shortened duration of antifungal therapy - CANDIDEMIA | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 362 | 2025-07-01 | 2025-03-05 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) SCY-078 - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Scynexis, Inc. | 30 | 2017-11-15 | 2024-07-03 |
| Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis micafungin, amphotericin B deoxycholate - Candidiasis | Phase 3 | Terminated | Astellas Pharma Global Development, Inc. | 30 | 2013-02-01 | 2015-11-04 |
| Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia Interferon-gamma, Recombinant - Candidemia | Phase 3 | Unknown | Radboud University Medical Center | 20 | 2011-01-01 | 2012-02-14 |
| A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis Anidulafungin/Fluconazole - Candidemia | Phase 3 | Terminated | Pfizer | 17 | 2010-12-01 | 2015-10-28 |
| An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System Active Anidulafungin, Active Caspofungin - Fungemia, Neutropenia | Phase 3 | Terminated | Pfizer | 21 | 2009-08-01 | 2012-12-20 |
| An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida Active anidulafungin, Active Caspofungin - Candidiasis, Fungemia | Phase 3 | Terminated | Pfizer | 41 | 2009-04-01 | 2013-08-01 |
| Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis Anidulafungin, Fluconazole - Candidemia | Phase 3 | Completed | Pfizer | 70 | 2009-02-01 | 2019-04-04 |
| A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections micafungin (Mycamine), itraconazole - Fungemia, Fungal Infections | Phase 3 | Completed | Astellas Pharma Inc | 288 | 2008-11-01 | 2016-03-28 |
| Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Anidulafungin, Fluconazole, Voriconazole - Invasive Candidiasis | Phase 3 | Completed | Pfizer | 216 | 2008-07-01 | 2011-05-30 |
| Anidulafungin In Treatment Of Candidemia In Asian Subjects Anidulafungin - Candidemia | Phase 3 | Completed | Pfizer | 43 | 2008-01-01 | 2010-03-09 |
| Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Isavuconazole, Caspofungin, Voriconazole - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 450 | 2007-03-08 | 2024-12-10 |
| Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Micafungin, Caspofungin - Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 611 | 2004-09-01 | 2014-09-18 |
| Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia Micafungin, fluconazole - Invasive Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 24 | 2004-08-01 | 2008-01-02 |
| The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis Anidulafungin, Fluconazole - Candidiasis | Phase 3 | Completed | Pfizer | 256 | 2003-03-01 | 2008-10-21 |
| Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia Micafungin, Liposomal Amphotericin B - Candidiasis | Phase 3 | Completed | Astellas Pharma Inc | 637 | 2003-01-01 | 2014-09-18 |
Showing 20 of 24. Sign in to see all of them.
Candidemia (20) · Candidiasis, Invasive (12) · Candidiasis (10) · Mycoses (10) · Torulopsis (5) · Aspergillosis (3) · Invasive Fungal Infections (3) · Sepsis (3) · Pathologic Processes (2) · Systemic Inflammatory Response Syndrome (2) · Bacteremia (1) · Infections (1) · Inflammation (1) · Neutropenia (1)
Bacterial Infections and Mycoses (24) · Pathological Conditions, Signs and Symptoms (24) · Infections (23) · Inflammation (23) · Pathologic Processes (22) · Systemic Inflammatory Response Syndrome (22) · Invasive Fungal Infections (21) · Sepsis (21) · Mycoses (14) · Candidiasis (12) · Candidiasis, Invasive (8) · Shock (2) · Agranulocytosis (1) · Bacterial Infections (1)
Fluconazole (10) · Micafungin (7) · Anidulafungin (6) · Caspofungin (5) · Voriconazole (4) · Injections (3) · Rezafungin (2) · ibrexafungerp (2) · Amphotericin B (1) · Echinocandins (1) · Interferon-gamma (1) · Itraconazole (1) · Standard of Care (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · amphotericin B, deoxycholate drug combination (1)
Pfizer (7) · Astellas Pharma Inc (5) · National Cancer Institute (NCI) (3) · Scynexis, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Global Development, Inc. (1) · Basilea Pharmaceutica (1) · BioWest Therapeutics Inc (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Mundipharma Research Limited (1) · Radboud University Medical Center (1)
United States (16) · Canada (9) · Belgium (8) · France (8) · Italy (8) · Germany (7) · Spain (7) · China (6) · Greece (6) · Brazil (5) · Bulgaria (5) · Israel (5) · Russia (5) · Taiwan (5) · India (4)
David Angulo, MD (2) · Alexandra Hill, MD (1) · Corine Delsing, MD (1) · Jim Pankovich (1) · Laura Cox, PhD (1) · Mihai Netea, MD PhD (1) · Shan-Chwen Chang, MD (1) · Taylor Sandison, MD, MPH (1)
PMID 28459966, PMID 28597967, PMID 33891293, PMID 31280481, PMID 21147825, PMID 33438477, PMID 17568028, PMID 19804626, PMID 22469884, PMID 23676114, PMID 24669841, PMID 25902926, PMID 29596222, PMID 30289478, PMID 30418357, PMID 32032174, PMID 36442484, PMID 37773627, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006
2008 (1), 2009 (1), 2017 (1)